v3.26.1
Product Sales year-on-year analysis: Q2 2026
6 Months Ended
Jun. 30, 2026
Product Sales year-on-year analysis: Q2 2026  
Product Sales year-on-year analysis: Q2 2026

Table 24: Product Sales year-on-year analysis: Q2 2026 (Unreviewed)

The Q2 2026 information in respect of the three months ended 30 June 2026 included in the Interim financial statements has not been reviewed by KPMG LLP.

World

US

Emerging Markets

Europe

Established RoW

For the quarter ended 30 June

Change

Change

Change

Change

Change

  ​ ​ ​

$m

  ​ ​ ​

Act %

  ​ ​ ​

CER %

  ​ ​ ​

$m

  ​ ​ ​

Act %

  ​ ​ ​

$m

  ​ ​ ​

Act %

  ​ ​ ​

CER %

  ​ ​ ​

$m

  ​ ​ ​

Act %

  ​ ​ ​

CER %

  ​ ​ ​

$m

  ​ ​ ​

Act %

  ​ ​ ​

CER %

Tagrisso

 

1,941

7

6

845

11

512

5

1

383

9

4

201

(3)

2

Imfinzi

 

1,854

27

27

1,054

25

211

39

36

398

39

34

191

10

17

Calquence

1,022

17

16

687

18

67

36

30

225

13

9

43

3

3

Lynparza

 

829

(1)

(3)

351

(7)

170

4

(2)

240

5

1

68

(2)

3

Enhertu

338

47

44

223

43

41

68

34

28

47

n/m

98

Zoladex

304

7

2

5

10

239

9

4

42

10

5

18

(23)

(24)

Truqap

 

233

37

37

168

18

17

n/m

n/m

34

n/m

n/m

14

77

85

Imjudo

83

(7)

(7)

51

(11)

7

(3)

(3)

14

25

20

11

(21)

(16)

Datroway

4

n/m

n/m

4

n/m

n/m

Etcamah

3

n/m

n/m

3

n/m

n/m

Other Oncology

 

102

(4)

(5)

2

58

69

(2)

(5)

4

(15)

(28)

27

(11)

(3)

Oncology

 

6,713

15

13

3,163

14

1,522

16

12

1,408

19

14

620

5

10

Farxiga

1,804

(16)

(19)

219

(48)

694

(19)

(24)

808

6

1

83

(22)

(19)

Crestor

 

331

4

1

10

(18)

299

9

5

22

(31)

(27)

Brilinta

80

(62)

(63)

2

(98)

66

5

3

11

(79)

(80)

1

(31)

(17)

Lokelma

 

221

26

26

85

13

48

47

40

47

54

46

41

12

22

Seloken

 

157

6

2

153

6

2

3

(1)

(3)

1

12

4

roxadustat

 

14

(81)

(82)

14

(81)

(82)

Wainua

70

58

58

64

50

1

n/m

n/m

4

n/m

n/m

1

n/m

n/m

Baxfendy

3

n/m

n/m

2

n/m

1

n/m

n/m

Other CVRM

 

91

(34)

(35)

(7)

n/m

70

5

2

14

(64)

(64)

14

(20)

(14)

CVRM

 

2,771

(15)

(18)

375

(44)

1,346

(11)

(15)

887

(4)

163

(16)

(12)

Symbicort

 

671

(6)

(8)

254

(20)

191

14

10

145

6

2

81

(12)

(14)

Fasenra

 

570

14

13

338

10

46

81

75

129

3

(1)

57

29

34

Breztri

346

22

20

161

9

93

43

35

62

36

31

30

23

26

Tezspire

172

54

51

24

n/m

n/m

107

49

42

41

33

41

Saphnelo

209

25

24

175

21

7

68

64

19

58

51

8

31

38

Pulmicort

 

120

13

9

2

11

97

20

15

14

(5)

(9)

7

(17)

(17)

Airsupra

 

50

19

18

45

9

5

n/m

n/m

Other R&I

 

69

13

9

7

(55)

27

(1)

(8)

33

n/m

n/m

2

6

5

R&I

 

2,207

11

9

982

490

29

24

509

21

16

226

9

11

Beyfortus

47

(52)

(52)

38

(49)

8

(66)

(67)

1

34

58

FluMist

18

79

78

(2)

n/m

1

n/m

n/m

19

90

82

Other ID

34

(31)

(34)

(1)

73

30

(20)

(26)

1

78

69

4

(68)

(66)

ID*

 

99

(37)

(38)

35

(52)

31

(18)

(24)

9

(62)

(64)

24

7

6

Ultomiris

1,314

12

12

719

8

87

42

41

307

14

9

201

12

19

Soliris

 

389

(27)

(28)

199

(29)

135

(15)

(19)

28

(50)

(50)

27

(21)

(22)

Strensiq

536

36

36

452

42

16

2

2

37

20

14

31

7

15

Koselugo

 

177

29

27

52

54

51

45

50

34

27

21

78

90

Other Rare Disease

74

36

33

30

8

13

n/m

n/m

20

11

5

11

n/m

n/m

Rare Disease

2,490

9

8

1,452

8

305

10

6

442

7

3

291

13

20

Other Medicines

230

(4)

(6)

19

(9)

166

(10)

(13)

25

52

51

20

12

14

Total Medicines

 

14,510

5

4

6,026

3

3,860

4

3,280

11

7

1,344

4

9

The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth.

* ID: Infectious Disease